FBXW7 and cancer: On one hand, MYC is an FBXW7 target (Yada et al, 2004) that stimulates mitochondrial biogenesis (Li et al, 2005; Lee et al, 2017), and increased levels of MYC have been shown to correlate with increased resistance to certain cancer therapies (Lee et al, 2017; Singleton et al, 2017).